Development of the Bone Phenotype and microRNA Profile in Adults With Low-Density Lipoprotein Receptor-Related Protein 5-High Bone Mass (LRP5-HBM) Disease.
HIGH BONE MASS
HR‐pQCT
LRP5
RARE MONOGENETIC BONE DISEASE
microRNA
Journal
JBMR plus
ISSN: 2473-4039
Titre abrégé: JBMR Plus
Pays: England
ID NLM: 101707013
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
27
01
2021
revised:
07
07
2021
accepted:
19
07
2021
entrez:
17
9
2021
pubmed:
18
9
2021
medline:
18
9
2021
Statut:
epublish
Résumé
Pathogenic variants in the Wnt-pathway co-receptor low-density lipoprotein (LDL) receptor-related protein 5 (LRP5) cause high bone mass (LRP5-HBM) due to insensitivity to the endogenous antagonist of Wnt-signaling. Although indicating incessant progression of BMD and biomarkers reflecting bone formation, this has not been confirmed in individuals with LRP5-HBM. We investigated how the LRP5-HBM bone phenotype changes with age in adults and is associated with quantitative changes of bone turnover markers and bone-related microRNAs (miRNAs) in the circulation. Whole body, lumbar spine, total hip, and femoral neck areal BMD (aBMD) and radial and tibial bone microarchitecture and geometry were assessed using DXA and HR-pQCT scans of 15 individuals with LRP5-HBM
Identifiants
pubmed: 34532618
doi: 10.1002/jbm4.10534
pii: JBM410534
pmc: PMC8441296
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10534Subventions
Organisme : Medical Research Council
ID : MR/P020941/1
Pays : United Kingdom
Informations de copyright
© 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
Déclaration de conflit d'intérêts
MH and MW report personal fees from TAmiRNA GmbH, outside the submitted work. RE reports grants from Amgen, grants and personal fees from IDS, grants from Alexion, grants and personal fees from Roche, personal fees from GSK Nutrition, personal fees from Mereo, personal fees from Sandoz, grants and personal fees from Nittobo, personal fees from AbbVie, personal fees from Samsung, personal fees from Haoma Medica, personal fees from Elsevier, personal fees from CL Bio, personal fees from FNIH, personal fees from Viking, personal fees from UCSF, personal fees from Biocon, from Lyramid, outside the submitted work.
Références
Eur J Endocrinol. 2013 Jul 13;169(2):R39-57
pubmed: 23744590
Osteoporos Int. 2019 Dec;30(12):2437-2448
pubmed: 31628490
Laryngoscope. 1988 Apr;98(4):411-3
pubmed: 3352441
J Cell Biochem. 2018 Apr;119(4):3293-3303
pubmed: 29125885
Oncol Lett. 2019 Jan;17(1):807-814
pubmed: 30655833
Biochim Biophys Acta. 2014 Nov;1839(11):1151-60
pubmed: 25151948
J Bone Miner Res. 1996 Nov;11(11):1745-50
pubmed: 8915782
J Clin Endocrinol Metab. 2016 Nov;101(11):4125-4134
pubmed: 27552543
Bone. 2015 Oct;79:43-51
pubmed: 26026730
Sci Transl Med. 2018 Nov 7;10(466):
pubmed: 30404864
J Bone Miner Res. 2012 Jun;27(6):1405-12
pubmed: 22407910
Cell Res. 2018 Sep;28(9):918-933
pubmed: 30030518
J Bone Miner Res. 2014 Mar;29(3):644-56
pubmed: 23929739
Am J Hum Genet. 2001 Mar;68(3):577-89
pubmed: 11179006
Osteoporos Int. 2012 Feb;23(2):643-54
pubmed: 21455762
J Biol Chem. 2005 Sep 30;280(39):33132-40
pubmed: 16043491
Bone Res. 2013 Mar 29;1(1):27-71
pubmed: 26273492
Bone. 2020 Jan;130:115105
pubmed: 31669252
J Cell Biochem. 2019 Sep;120(9):15429-15442
pubmed: 31111563
Cell Death Dis. 2013 Oct 10;4:e845
pubmed: 24113179
PLoS One. 2018 Feb 15;13(2):e0193059
pubmed: 29447276
Hum Mol Genet. 2001 Mar 1;10(5):537-43
pubmed: 11181578
Cell Biol Int. 2016 Dec;40(12):1271-1279
pubmed: 27542661
J Bone Miner Res. 2016 Aug;31(8):1541-9
pubmed: 26896351
Calcif Tissue Int. 2020 Mar;106(3):239-247
pubmed: 31729554
Am J Hum Genet. 2002 Jan;70(1):11-9
pubmed: 11741193
Cell Mol Gastroenterol Hepatol. 2015 Sep 1;1(5):535-549.e14
pubmed: 26473164
J Clin Endocrinol Metab. 2018 May 1;103(5):1985-1996
pubmed: 29506076
Bone. 1993 Nov-Dec;14(6):865-9
pubmed: 8155410
Cell. 2001 Nov 16;107(4):513-23
pubmed: 11719191
J Bone Miner Res. 2018 Aug;33(8):1397-1406
pubmed: 29694685
Oncotarget. 2017 Oct 4;8(50):88163-88178
pubmed: 29152149
Endocrine. 2016 Jun;52(3):414-26
pubmed: 26892377
Mol Cell Endocrinol. 2016 Sep 5;432:83-95
pubmed: 26525415
PLoS One. 2016 Apr 07;11(4):e0153200
pubmed: 27054342
Osteoporos Int. 2002;13(2):105-12
pubmed: 11905520
Bone. 2017 Dec;105:93-102
pubmed: 28739416
J Bone Miner Res. 2011 Aug;26(8):1721-8
pubmed: 21351148
J Bone Miner Res. 2011 Aug;26(8):1953-63
pubmed: 21351149
N Engl J Med. 2002 May 16;346(20):1513-21
pubmed: 12015390
J Med Genet. 2002 Feb;39(2):91-7
pubmed: 11836356
J Bone Miner Res. 2016 Jan;31(1):65-75
pubmed: 26189772
Int J Mol Med. 2006 May;17(5):795-9
pubmed: 16596263
J Bone Miner Res. 2016 Sep;31(9):1734-42
pubmed: 27005318
Bonekey Rep. 2016 Sep 21;5:839
pubmed: 27688878
Am J Transl Res. 2017 Jan 15;9(1):136-145
pubmed: 28123640
Bone. 2019 Oct;127:228-243
pubmed: 31085352
N Engl J Med. 2017 Oct 12;377(15):1417-1427
pubmed: 28892457